-
-
-
-
-
-
-
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
-
-
-
-
-
-
-
RBC Capital Downgrades Avidity Biosciences (RNA) to Sector Perform
-
-
-
-
-
-
-
Raymond James Downgrades Avidity Biosciences (RNA) to Market Perform
-
-
-
-
-
-
-
Avidity Biosciences Inc. (RNA) files for 15M share offering
-
-
-
-
-
-
-
Dyne Therapeutics Inc. (DYN) gains following Avidity Biosciences Inc. (RNA) Takeover Rumors, Up 24%
-
-
-
-
-
-
-
Avidity Biosciences Inc. (RNA) Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD
-
-
-
-
-
-
-
Citi Reiterates Buy Rating on Avidity Biosciences (RNA)
-
408,165 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

